Properties
What is it?
International Nonproprietary Name - dexamethasone Clinical-pharmacological group: Ophthalmology → Anti-inflammatory agents for topical use in ophthalmology → Glucocorticosteroids Contents: 1 ml of the preparation contains: Active substances: Dexamethasone sodium phosphate – 1.32 mg (equivalent to 1 mg dexamethasone) Excipients: Benzalkonium chloride, boric acid, sodium tetraborate, disodium edetate, water for injection. Description: Clear, colorless solution. Dosage form: Eye drops 1 mg/ml In a 5 ml polyethylene dropper bottle with a plastic tip and screw cap. The dropper bottle is placed in a cardboard box along with the instructions for use. Indications: Acute and chronic inflammatory processes: - Non-purulent forms of conjunctivitis, keratitis, keratoconjunctivitis without epithelial damage and blepharitis; - Scleritis and episcleritis; - Iritis, iridocyclitis and uveitis of various origins; - Superficial corneal lesions of various etiologies (chemical, physical, and immune mechanisms) after complete corneal epithelization; - Inflammation of the posterior segment of the eye (choroiditis, chorioretinitis); - Sympathetic ophthalmia. Allergic diseases of the eyes: - Allergic conjunctivitis and keratoconjunctivitis. Prevention and treatment of inflammatory events in the postoperative and post-traumatic period. Contraindications: - Keratitis associated with herpes simplex, varicella, and other viral diseases of the cornea and conjunctiva; - Ocular tuberculosis; - Ocular mycobacterial infections; - Ocular fungal diseases; - Acute purulent diseases of the eye; - Damage to the corneal epithelium (including the condition after removal of a foreign body from the cornea); - Corneal epitheliopathy; - Increased intraocular pressure; - Glaucoma; - Children under 18 years of age (due to lack of data on the efficacy and safety of the preparation in children and adolescents); - Hypersensitivity to any component of the preparation. Dosage and administration: In acute conditions: 1-2 drops in each conjunctival sac every 1-2 hours. After reduction of inflammation, Oftan® Dexamethasone eye drops are instilled into the conjunctival sac, 1-2 drops 3-5 times a day. The duration of treatment with Oftan® Dexamethasone eye drops should not exceed 2-3 weeks. The decision on the duration of treatment is based on objective data, including the effectiveness of the preparation's action, the severity of clinical symptoms, and the possible risk of side effects. Side effects: After instillation of Oftan® Dexamethasone eye drops, a rapidly transient burning sensation and allergic reactions may occur. Prolonged use of dexamethasone (more than 3 weeks) can cause secondary glaucoma and steroid cataracts, as well as ulceration, clouding, thinning, or perforation of the cornea. In rare cases, dexamethasone may contribute to the spread of herpetic and bacterial infections. Oftan® Dexamethasone contains benzalkonium chloride as a preservative, which can cause eye irritation. If side effects occur, consult your doctor immediately.
